April 20, 2016
Research shines new light on malignant hyperthermia
The rare but very serious condition of malignant hyperthermia (MH) remains a risk at all surgical facilities, including ambulatory surgical centers (ASCs). MH occurs in about one in 50,000 adults under anesthesia, and one in about 12,000 children, which translates to one or two deaths annually in the United States. When it does strike, MH often is fatal if not treated within minutes. And the only antidote is a very expensive drug.
Free Daily News
- Anthem’s anesthesia time limit policy, reversal sparks new legislation
- Simple procedure or ‘surgery’? Questionable medical billing practices cause confusion
- Antitrust guideline withdrawal could dampen M&A, boost uncertainty for provider joint ventures
- Surgeons emphasize bariatric surgery benefits amid rising GLP-1 drug popularity
- Study: Geriatric surgery program improves outcomes, independence
- Milestone pig kidney transplant offers hope amid ethical, safety questions
- Fitch Ratings: Hospital credit outlook improves amid stabilizing margins
- Annual Leapfrog Group awards recognize top hospitals, ASCs
- US obesity rates decline for first time in a decade
- Study: Active monitoring without surgery safe for certain low-risk DCIS patients
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement